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Patients with relapsed or refractory advanced T cell non-Hodgkin lymphoma have a dismal prognosis and
may not even reach allogeneic hematopoietic stem cell transplantation (HSCT) in adequate condition. We
present the outcome of 24 consecutive patients (age range 11 to 65 years) treated at a single institution in Kiel
within a recent 5.5-year time frame with allogeneic HSCT in a rather uniform approach. Relapsed and
refractory T and natural killer cell lymphomas of various subtypes were included. All patients except 1 were in
progression or relapse before start of pretransplantation salvage therapy. Five patients had relapsed after
autologous HSCT. With intensive remission induction therapy, usually the CLAEG (cladribine, cytosine
arabinoside, and etoposide with granulocyte colony-stimulating factor support) protocol, attempts were
made to improve disease control and proceed immediately to conditioning with carmustine, etoposide,
cytosine arabinoside, melphalan (BEAM), and medium-dose alemtuzumab. Twenty of 21 patients who
received CLAEG induction therapy beneﬁted from this protocol and 1 patient appeared to be therapy-
resistant. At the time of allogeneic HSCT, 9 patients were in complete remission (CR) (2 in CR1, 5 in CR2,
and 2 in CR >2), whereas 50% had never achieved CR. Nineteen transplants were obtained from matched or
partially matched unrelated donors and only 5 from siblings. With a median follow-up of 321 days (1252 days
for surviving patients), 20 of 22 assessable patients reached CR. Five of these patients had hematologic or
molecular relapse. With donor lymphocyte infusions, 1 patient became minimal residual disease MRD
negative again and has maintained CR for more than 4 years. The frequency of grades II to IV acute graft-
versus-host disease was 25% and chronic graft-versus-host disease, 30%. Intense reinduction therapy fol-
lowed by reduced-intensity BEAM-alemtuzumab conditioning and allogeneic HSCT is effective and offers
curative potential for patients with advanced T cell lymphomas, even for those not in remission.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
With few exceptions, patients with T cell non-Hodgkin
lymphoma (NHL) have a very limited prognosis [1-4]. The
inclusion of autologous hematopoietic stem cell trans-
plantation (HSCT) in frontline therapy did result in improved
survival for patients with very good responses, although
many patients progressed before reaching transplantation
[5-8]. New therapeutic agents, including pralatrexat, Histone
deacetylase HDAC inhibitors such as vorinostat, and bren-
tuximab vedotin for CD30-positive patients, have been
introduced [9]. Their deﬁnite place in the clinical arena is yet
to be determined. The CD52 monoclonal antibody alemtu-
zumab (also known as CAMPATH-1H) has already shown its
therapeutic potential [10,11]. Alemtuzumab became the
standard of care in T cell prolymphocytic leukemia, but it
lacks curative potential when not followed by an allogeneicedgments on page 1636.
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13.07.003HSCT [12]. Induction chemotherapy regimens, such as CHOP,
have been combined with alemtuzumab for peripheral T cell
lymphoma. Although high remission rates could be achieved,
they were often not durable and complications seen often
were severe infections [13]. Because alemtuzumab recog-
nizes CD52 on normal and malignant T cells, immunosup-
pression is inevitable. However, in the setting of allogeneic
HSCT, this feature can be used to prevent severe graft-versus-
host disease (GVHD) from compromising outcome. In fact,
Faulkner et al. [14] proposed a slightly modiﬁed carmustine,
etoposide, cytosine arabinoside, melphalan (BEAM) protocol
with alemtuzumab suitable for reduced-intensity condi-
tioning of lymphoma patients. This protocol appears to be
well tolerated and efﬁcient also in T cell malignancies.
The necessity to respond therapeutically to often rapidly
progressing T cell lymphomas led to the approach presented
here. Intense pretherapy was followed by immediate
conditioning. The protocol for remission induction called for
cladribine, cytosine arabinoside, and etoposide with gran-
ulocyte colony-stimulating factor support (CLAEG) [15]. An
immediate donor search was initiated. All efforts were made
to keep the interval between pretreatment and conditioningTransplantation.
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regimen to destroy residual tumor cells and to reduce severe
GVHD.
METHODS
Patient Characteristics
Between June 2005 and December 2010, all 24 patients consecutively
referred to our institution at the Division for Stem Cell Transplantation and
Immunotherapy in Kiel with relapsed or refractory T cell lineage neoplasms
were considered to be submitted to allogeneic HSCT. The 24 patients, 18men
and 6 women, 2 children and 22 adults, had a median age at the time of
allogeneic HSCT of 53 years (range, 11 to 65 years). Nine patients had
peripheral T cell lymphoma, not otherwise speciﬁed; 5 patients had
angioimmunoblastic T cell lymphoma; 4 patients had anaplastic large cell
lymphoma, 1 anaplastic lymphoma kinase (ALK) positive and 3 ALK nega-
tive; 2 had enteropathy-associated T cell lymphoma; 1 had T cell prolym-
phocytic leukemia; 1 had extranodal natural killer (NK)/T cell lymphoma,
nasal type; 1 patient had NK/T cell lymphoma; and 1 patient had lympho-
blastic T cell lymphoma. At the time of initial diagnosis, 18 patients had stage
IV disease, 3 patients showed stage III, and 3 patients stage II disease. For an
overview of patients’ characteristics, see Table 1.
Prior Treatment
Two median lines of therapy were administered before remission
induction with CLAEG and subsequent allogeneic HSCT (range, 0 to 4: 9
patients received 1 regimen, 11 patients 2 protocols, 3 patients 4, and 1
patient was heavily pretreated for Hodgkin’s disease). Four patients had
previously received high-dose chemotherapy with autologous HSCT, and 1
additional patient had previously received 3 cycles of MegaCHOEP followed
by autologous HSCT (Table 1) [16]. Five patients received previous radio-
therapy, and 1 patient with enteropathy-associated T cell lymphoma
underwent surgery before high-dose chemotherapy. One patient who later
relapsed received a second allogeneic transplant from a different unrelated
donor. In this case, donor lymphocyte infusions (DLIs) were administrated
before the second transplantation.
CLAEG Protocol
Before allogeneic HSCT, patients were usually pretreated with the
CLAEG protocol [15] to induce remission or consolidate remission status
and allow time for a donor search. The CLAEG regimen consists of cla-
dribine 0.2 mg/kg/day as an i.v. infusion over 2 hours on days 1 to 5, eto-
poside 60 mg/m2/day on days 1 to 5, and cytosine arabinoside 1.5 g/m2/day
on days 1 to 5. From day 6 onward, granulocyte colony-stimulating fator
(ﬁlgastrim) was administered. A second cycle of CLAEG was given in 9
patients. One patient who received 2 cycles of the CLAEG protocol was
resistant, and 3 patients had considerable tumor burdens early after CLAEG
and received additional bridging therapy before allogeneic HSCT (see Table 1
for details). Three patients were treated for individual reasons with different
regimens before HSCT: 1 received gemcitabine, 1 alemtuzumab, and 1 vor-
inostat (Table 1). All attempts were made to directly start conditioning of
allogeneic HSCT after recovery.
Stem Cell Source
For all transplant candidates, a donor was found. The source of stem
cells was peripheral blood (n ¼ 22) or bone marrow (n ¼ 2). The median
CD34þ cell dose was 6.6  106/kg (range, 2.46  106/kg to 16.1  106/kg).
Only 5 patients had an HLA-matched sibling donor, whereas 19 were
transplanted with grafts of unrelated donors. Although 14 were by high-
resolution typing from 10/10 HLA matched unrelated donors, 5 were
transplanted from allele or antigen mismatched unrelated donors, namely 3
of these with 1 mismatch, and 2 with more than 2 mismatches, respectively.
There were 12 patientedonor pairs with moderate risk and 5 with high risk
for cytomegalovirus reactivation.
Transplant Procedure
Twenty-one patients received the BEAM regimen with alemtuzumab
[14]. BCNU (carmustine) 300 mg/m2 was administered as an infusion on
day 7, cytosine arabinoside 200 mg/m2 on days 6 to 3, etoposide
200 mg/m2 on days 6 to 3, and melphalan at 140 mg/m2 on day 2.
Usually, 10 mg of alemtuzumab was infused i.v. on days 6 to 2. In 3
patients, 2 of whomwere pretreatedwith a BEAM conditioning regimen due
to previous autologous HSCT, a reduced dose of BCNU was given. Three
patients, for various reasons, received alternative conditioning regimens as
indicated in Table 1. Nine patients received post-transplant GVHD prophy-
laxis based on cyclosporine A (CSA) and short-coursemethotrexate, whereas
12 patients had CSA with mycophenolate mofetil, and 3 patients CSA only.All patients recovered in single rooms with ﬁltered air and reverse
barrier isolation from the beginning of the conditioning until bone marrow
engraftment. A prophylactic antibiotic therapy for gut decontamination
with ﬂuconazole, ciproﬂoxacin, and colistin was scheduled. Quantitative
cytomegalovirus monitoring was performed by PCR.Statistical Analysis
Overall survival (OS) was deﬁned as the time from transplantation to
death or last patient contact. Event-free survival was deﬁned from date of
transplantation to date of relapse or progression, death of any cause, or last
contact with a patient in continuous complete remission (CR). Progression-
free survival was deﬁned from date of transplantation to date of relapse or
progression, or last contact with a patient in continuous CR. Survival times
were compared by performing a log-rank test of the Kaplan-Meier estimates
of OS and progression-free survival [17]. Median observation time of event-
free subjects was calculated according to Schemper and Smith [18].
For all statistical comparisons, a 2-sided P  .05 was considered to be
statistically signiﬁcant. Statistical calculations were performed using R
(http://www.r-project.org, R version 2.15.1 [2012-06-22], packages base,
lattice, odfWeave, survival, XML).RESULTS
Disease Status of Patients Undergoing Transplantation
To improve disease control, CLAEG was given in most
patients, and to prevent early progress, all attempts were
made to schedule allogeneic transplantation as soon as
possible after prior chemotherapy. All patients except 1 were
in progression or relapse before CLAEG salvage therapy.
Twenty of 21 patients who received CLAEG induction therapy
beneﬁted from this protocol, and only 1 patient appeared to
be resistant to therapy. The median time from ﬁrst day of last
prior therapy to start of conditioning was only 34.5 days
(range, 20 to 85 days). At the time of HSCT, 12 patients had
never achieved CR before undergoing the transplant proce-
dure; 2 patients were in CR1, 5 patients in CR2, 2 patients in
CR >2, 6 patients in ﬁrst partial remission, 4 patients in
second partial remission, 1 patient had stable disease,
1 patient was primarily refractory to induction therapy, and 1
patient had resistant relapse. Two patients were trans-
planted in responding relapse. Details are given in Table 1.
Toxicity and Infectious Complications
Acute toxicity was moderate. Although 7 patients showed
no signs of mucositis, grade IV mucositis occurred in 8
patients, whereas grade III, grade II, and grade I occurred in 3
patients each (Table 2). No cases of VOD were observed. All
patients developed neutropenic fever and were treated with
intravenous antibiotics. Seven patients developed pneu-
monia, and 6 patients experienced sepsis, with fatal outcome
in 3 of these patients. Two early deaths occurred from
infectious causes, 1 while the patient was still severely
neutropenic.Engraftment and Chimerism Analysis
One patient died at day þ24, before hematological
recovery, and was excluded from engraftment analysis. No
primary graft failure occurred. The median time to leukocyte
count1000/nLwas 15.5 days (Table 2). Platelet engraftment
(platelets >20/nL without transfusion support) occurred on
day þ13 (median; range, 8 to 408 days; Table 2). Three
patients were treated with alemtuzumab as bridging therapy
shortly before the start of conditioning. Although all
engrafted without delay, 1 of these patients showed late
platelet engraftment on day þ408. Although he received
a stem cell boost and DLIs, only when the diagnosis of
atypical mycobacterial infection with Mycobacterium gena-
vense was established and a 4-drug antibiotic regimen
Table 1
Patients Characteristics and Treatment
Patient
No.
UPN Diagnosis Age (yr) Sex LoT before
CLAEG
Previous
ASCT
CLAEG
(Courses)
Status at HSCT Conditioning
Regime
Campath
Dose (mg)
Graft
Source
Donor Type CD34þ/kg  106 GVHD
Prophylaxis
CMV
Status R/D
1 1220 ALCL, ALK neg. 58 f 4 Yes 1 Responding relapse BEAM/Cam 70 PBSC MUD 10.7 CSA/MTX n/n
2 1234 PTCL-NOS
lymphoepithelioid
34 m 1 - 2 SD BEAM/Cam 50 PBSC MRD 10.7 CSA/MTX/MMF p/p
3 1244 EATL 58 m 2 - 2y Resistant relapse BEAM/Cam 50 PBSC MUD 8 CSA/MMF p/n
4 1263 PTCL-NOS 57 m 4 - 1y PR2, never CR BEAM/Cam 50 PBSC MUD 6 CSA/MMF p/p
5 1283 PTCL-NOS 44 m 2 Yes* y CR2 Mel/Flu/TT/Cam 70 PBSC MMUD 2þ 6.3 CSA/MMF n/n
6 1310 EATL, ALK neg. 54 m 2 Yes 1y CR>2 BEAM/Cam 50 PBSC MUD 8,5 CSA/MTX p/n
7 1338 PTCL-NOS,
lymphoepithelioid
54 f 2 - 1 PR2, never CR BEAM/Cam 50 PBSC MRD 6.28 CSA/MMF p/p
8 1349 AITL 38 m 1 - 2 Ref BEAM/Cam 50 PBSC MUD 5.48 CSA/MMF p/p
9 1351 AITL 36 m 0z - 2 PR1, never CR BEAM/Cam 50 BM MMUD 1 4.2 CSA/MTX n/n
10 1369 EN nasal type 11 m 2 - 2 PR1, never CR BEAM/Cam 35 PBSC MUD 16.1 CSA/MTX n/n
11 1398 T-PLL 53 f 1 - y CR1 BEAM/Cam 50 PBSC MUD 4.96 CSA/MTX p/n
12 1400 PTCL-NOS 63 m 4 Yes y responding relapse Flu/TBI/2Gy/Cam 73 PBSC MUD 8.2 CSA p/p
13 1431 ALCL, ALK pos. 28 m 2 Yes 1 CR>2 BEAM/Cam 50 PBSC MRD 5.5 CSA/MTX n/p
14 1448 Blastic NK-T cell 32 m 1 - 2 CR2 BEAM/Cam 50 PBSC MUD 8.67 CSA/MTX n/n
15 1559 PTCL-NOS 65 f 1 - 2 CR1 BEAM/Cam 50 PBSC MUD 5.14 CSA/MTX p/n
16 1582 AITL 53 m 1 - 1 CR2 BEAM/Cam 50 PBSC MRD 6.94 CSA/MMF p/p
17 1598 ALCL, ALK neg. 54 m 2z - 1 PR1, never CR BEAM/Cam 50 PBSC MRD 8.25 CSA/MMF p/p
18 1615 ALCL, ALK neg. 65 m 2 - 1 CR2 BEAM/Cam 50 PBSC MUD 6.91 CSA/MMF p/p
19 1623 PTCL-NOS 57 m 2 - 2 PR1, never CR BEAM/Cam 50 PBSC MMUD 1 9.6 CSA/MMF n/n
20 1677 PTCL-NOS 52 m 1 - 1y PR2, never CR BEAM/Cam 50 PBSC MUD 6.21 CSA p/p
21 1694 AITL 54 m 2 - 1 PR2, never CR BEAM/Cam 90 PBSC MUD 5.89 CSA/MMF p/p
22 1717 AITL 51 f 1 - 1 CR2 BEAM/Cam 50 PBSC MUD 8.03 CSA/MMF n/n
23 1743 Lymphoblastic TCL 11 m 2 - 1 PR1 TBI/VP16/ATG 0 BM MMUD 1 2.46 CSA p/n
24 1748 PTCL-NOS 26 f 1 - 2 PR1, never CR BEAM/Cam 30 PBSC MMUD 2þ 6.2 CSA/MMF p/p
UPN indicates unique patient number; ASCT, autologous stem cell transplantation; f, female; m, male; ALCL, anaplastic large cell lymphoma; ALK neg./pos., anaplastic lymphoma kinase-1 negative/positive; PTCL-NOS, peripheral
T cell lymphoma, not otherwise speciﬁed; AITL, angioimmunoblastic T cell lymphoma; EN, extranodal natural killer/T cell lymphoma; T-PLL, T cell prolymphocytic leukemia; EATL, enteropathy-associated T cell lymphoma; TCL, T
cell lymphoma; PR, partial remission; SD, stable disease; Ref, primary refractory disease; BEAM, BCNU (carmustine)/etoposide/ara-C (cytarabine)/melphalan; Mel, melphalan; TT, thiotepa; Cam, Campath 1-H/alemtuzumab; Flu,
ﬂudarabine; TBI, total body irradiation; VP16, etoposide; ATG, antithymocyte globulin; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; MRD, matched related donor; CSA, cyclosporine A; MTX,
methotrexate; MMF, mycophenolate mofetil; R, recipient; D, donor; p, positive; n, negative; LoT, lines of treatment.
* Dose-escalated CHOEP followed by 3 times repeated ASCT.
y Additional or different therapy from CLAEG: UPN1244, cyclophosphamide; UPN1263, MTX and asparaginase; UPN1283, gemcitabine; UPN1310, alemtuzumab 330mg; UPN1398, alemtuzumab 223mg; UPN1400, vorinostat;
UPN1677, MTX and alemtuzumab 223 mg.
z Patients pretreated for Hodgkin disease: UPN1351, 2 regimens, and UPN1598, 1 regimen.
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Figure 1. Overall survival probability from time of transplantation is given and
median is indicated. The numbers of patients at risk are provided.
Table 2
Follow-up after Allogeneic HSCT
Patient
No.
UPN Mucositis
(Grade)
Infections
During
Initial HSCT
WBC >1/nL
(Day)
PLT > 20/nL
(Day)
Acute GVHD
(Grade)
Chronic GVHD
(Grade)
Best
Response
DLI Survival
(Status, Days)
Comments
1 1220 IV No 13 14 I None CR No Died þ504 R þ457, sepsis
2 1234 II No 12 17 0 None CR No Alive þ789 CR
3 1244 II No 11 13 0 Limited CR No Died þ231 CR, pneumonia
4 1263 None No 10 8 I None CR No Alive þ1627 CR, BCC
5 1283 I S 13 10 II Extensive CR No Alive þ1871 CR, cGVHD
6 1310 I No 20 408 II None CR Yes Alive þ1363 CR, SCB, DLI, atypical
mycobacterial infection
7 1338 None No 17 12 0 Extensive CR No Alive þ1695 CR, cGVHD
8 1349 IV S 13 14 0 None CR Yes Died þ606 R þ353, alemtuzumab,
DLI, PTLD
9 1351 IV P 19 18 0 None PR No Died þ281 PD þ80 with CNS
involvement, ara-C,
alemtuzumab
10 1369 None S 25 34 II None CR No Alive þ1400 CR
11 1398 III S 18 9 0 Limited CR Yes Alive þ1413 Molecular R on day þ334,
alemtuzumab, DLI,
continuous CR
12 1400 None S NA NA 0 NA NA No Died þ24 Sepsis, peritonitis, MOF
13 1431 I P 15 12 II Limited CR No Alive þ1141 PD þ36, excision of LN,
vincristine, doxorubicin,
bortezomib, withdrawal
of immunosuppression,
continuous CR
14 1448 III S, P 17 14 0 NA CR No Died þ45 CR, sepsis, pneumonia
15 1559 IV P 24 14 I None CR No Died þ113 R þ73, alemtuzumab,
pentostatin
16 1582 IV No 13 11 0 None CR yes Died þ328 CR, DLI, pancreatitis
17 1598 None No 15 10 0 None PR No Died þ120 PD þ75, bortezomib,
cyclophosphamide,
alemtuzumab, sepsis
18 1615 None No 12 13 0 None CR No Died þ125 CR, liver cirrhosis and
acute liver failure
19 1623 II P 14 11 I Extensive CR Yes Died þ456 R þ210, DLI, second HSCT,
sepsis, MOF, ACS
20 1677 III No 15 13 I None CR No Alive þ314 CR
21 1694 IV P 23 NR IV NA NA No Died þ38 aGVHD, infection
22 1717 None No 14 7 II None CR No Alive þ124 CR
23 1743 IV No 24 28 I None CR No Alive þ106 CR, HHV6 infection, SCB
24 1748 IV P 12 9 I NA CR No Alive þ90 CR
UPN indicates unique patient number; S, sepsis; P, pneumonia; WBC, white blood cell count; PLT, platelet count; NA, nonassessable; NR, not reached; a/cGVHD,
acute/chronic graft-versus-host disease; PR, partial remission; PD, progressive disease; R, relapse; DLI; donor lymphocyte infusion; BCC, basal cell carcinoma;
PTLD, post-transplant lymphoproliferative disorder; CNS, central nervous system; MRD, minimal residual disease; SCB, stem cell boost; LN, lymph node; MOF,
multiple organ failure; ACS, acute coronary syndrome; HHV6, human herpes virus 6.
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dramatically improve.
Response
Overall, there were 12 deaths. Although 6 were treatment
related, another 6 were disease related, namely 4 relapses
and 2 progressions. Response was assessable in 22 cases.
Twenty of 22 assessable patients reached CR after allogeneic
HSCT. Among themwere 11 patients who had never achieved
CR before Two patients who underwent allogeneic trans-
plantation in partial remission did not improve their disease
statuses and, despite salvage therapy, died due to progres-
sion at day þ120 or day þ281, respectively. Three of 5
patients who relapsed after previous autologous HSCT ach-
ieved durable CR after allogeneic HSCT (Table 2).
Median follow-up of event-free patients was
44.8 months. At the time of last follow-up, 12 of 24 patients
(50%) were alive and in CR. Median OS was 16.6 months
(Figure 1). Overall, survival at 100 days, 1 year, and 3 years
was 87.5% (95% conﬁdence interval, 75.2% to 100.0%), 58.3%
(95% conﬁdence interval, 40.6% to 83.8%), and 42.4% (95%
conﬁdence interval, 25.4% to 70.8%), respectively, with
a stable plateau. A short interval between salvage therapyand HSCT was associated with a tendency toward both
superior OS (P ¼ .054) and event-free survival (P ¼ .094).
The small number of patients in each histological subgroup
limited comparison; however, when angioimmunoblastic
Figure 2. Probability of freedom from progression from time of trans-
plantation. The median is not reached. The numbers of patients at risk are
provided.
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phoma, and peripheral T cell lymphomas, which were not
otherwise speciﬁed were correlated for outcome with other
entities, ALK-negative anaplastic large cell lymphoma
showed a trend toward poorer OS (P ¼ .12).
Only 5 of 20 patients who achieved CR after allogeneic
transplantation relapsed (status before HSCT: 2 CR, 1 partial
remission, 1 responding relapse, and 1 primary refractory).
The median time to relapse after allogeneic HSCT was
343 days. Patients who did not relapse within the ﬁrst
15 months enjoyed long-term progression-free survival
(Figure 2). One patient with positive minimal residual
disease after transplantationwas administered DLIs, and this
patient remains in continuous molecular remission (last
follow-up, dayþ1413). Two additional patients who relapsed
were treated with DLI. One patient developed B cell post-
transplant lymphoproliferative disease and died with
severe acute GVHD. After the DLI therapy, the other patient
underwent a second allogeneic transplantation from
a different unrelated donor but died from multiple organ
failure 28 days after the second allogeneic transplantation.
Frequency of GVHD
Frequency of acute GVHD was low. Of the 13 patients
affected, 7 patients had grade I, 5 patients presented with
grade II, and 1 patient had signs of acute GVHD grade IV. This
patient died due to severe acute GVHD complicated by an
infection. Chronic GVHD occurred in 6 of 20 assessable cases.
Three patients had limited chronic GVHD, and 3 patients
developed extensive chronic GVHD (Table 2).
DISCUSSION
With few exceptions, patients with peripheral T cell
lymphomas have a limited prognosis [19]. Although some
patients transplanted in CR1 may beneﬁt from autologous
HSCT at least in the relapse situation, the contribution is
limited and the outlook remains grim [7,8,20-22]. When T
cell lymphoma patients progress or relapse, no standard
second-line salvage regimen is available. This also applies to
patients with cutaneous involvement when speciﬁc derma-
tological therapy has been exhausted. Recently introduced
agents such as vorinostat [23], romidepsin [24], pralatrexat
[25], nelarabine [26], CD4monoclonal antibody zanolinumab
[27], or CD30 antibody drug conjugate brentuximab vedotin
[28] offer some advantages for certain T cell NHL patients,although it remains to be seen whether long-term contin-
uous complete remission CCR in pretreated T cell NHL is
achievable in many. In a consistent pattern, T cell lymphoma
patients treated with allogeneic HSCT have been shown to
reach stable CCR. Not surprisingly, however, selected patients
in different disease phases or heterogeneous registry data
and patients transplanted predominantly with sibling
donors, non-uniform conditioning, and pretreatment proto-
cols oftenwere reported and single-center results were often
not obtained in a short time span [29-34].
Unfortunately, after achieving ﬁrst remission upon
chemotherapy and even after frontline autologous HSCT, T
cell NHL patients may relapse rapidly and vigorously. In
particular, elderly patients may appear, for the treating
physicians outside a transplant center, to be too frail to
undergo allogeneic HSCT. In addition, it may be difﬁcult to
achieve disease control and a donor has yet to be identiﬁed.
Thus, remission induction or at least stabilizing chemo-
therapy is of utmost importance while a fast-track donor
search must be initiated. Here, we demonstrate, in 24
consecutive patients referred to our institution in a recent
time span, that with a short interval between last prior
chemotherapy, all patients could undergo allogeneic HSCT.
In most patients, the CLAEG protocol was effective in
tumor control and tolerable despite induction of signiﬁcant
aplasia. Still a matter of debate, our data support that NHL
patients, despite not achieving remission, can beneﬁt from
allogeneic HSCT. After BEAM- alemtuzumab conditioning,
almost one half of the patients achieved CR for the ﬁrst time.
Antibody efﬁcacy due to antigen sink effects depends on the
amount of CD52-positive tumor cells still present at the time
of conditioning. However, the intermediate dose of alemtu-
zumab added to BEAM, as originally proposed by Faulkner
et al. [14], may not only have been adequate for reducing
remaining T cells, but may also be a reasonable dose for
prophylaxis for GVHD, because severe acute and chronic
GVHD were moderate and long-term tumor control was not
compromised.
As previously described [32-35], DLIs in those T cell NHL
patients who relapsed with limited disease may still allow
deﬁnite lymphoma control. In fact, also in the study presented
here, 2 patients who relapsed after transplantation achieved
a CR upon DLI application. However, although 1 of these
patients remains after years inCCR, another patient developed
severe GVHD.
This report of 24 patients with T cell NHL accrued in
a single center in a recent 5.5-year time frame demonstrates
that the suggested treatment protocol is logistically feasible,
well tolerated, and efﬁcient. With fast-track search strate-
gies, matched unrelated donors can be found rapidly today,
whereas it is important meanwhile to improve the remission
status with an effective induction protocol. CLAEG appears to
be such a protocol for many patients with T cell NHL and,
even more important, allows conditioning to start without
delay. Particularly in highly proliferative T cell tumors, this
short time span from preceding chemotherapy to BEAM-
alemtuzumab seems to be important. With this reduced-
conditioning protocol, even elderly patients and those in
limited physical condition can be successfully transplanted.
When T cell lymphoma patients are referred earlier to such
a treatment approach, the results may even improve further.
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